About: Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19
Creator	Blumberg, Lucille Kano, Shigeyuki Dupouy-Camet, Jean Marty, Aileen Jones, Malcolm Bienvenu, Anne-Lise Carnevale, Pierre Daniel-Ribeiro, Tadeu Mas-Coma, Santiago Picot, Stephane
Source	Elsevier; Medline; PMC
abstract	Our coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure drug for exposed people, meaning people with close contact with positive tested patients, including home and medical caregivers. We have reviewed the mechanisms of antiviral effect of HCQ, the risk-benefit ratio taking into consideration the PK/PD of HCQ and the thresholds of efficacy. We have studied its use as an antimalarial, an antiviral, and an immunomodulating drug and concluded that the use of HCQ at does matching that of the standard treatment of Systemic Lupus erythematous, which has proven safety and efficacy in terms of HCQ blood and tissue concentration adapted to bodyweight (2,3), at 6 mg/kg/day 1 (loading dose) followed by 5 mg/kg/day, with a maximum limit of 600 mg/day in all cases should swiftly be clinically evaluated as a post-exposure drug for exposed people.
has issue date	2020-04-04(xsd:dateTime)
bibo:doi	10.1016/j.onehlt.2020.100131
bibo:pmid	32292817
has license	no-cc
sha1sum (hex)	630cf094987dd0a567cd7d4373e10928245f5dd6
schema:url	https://doi.org/10.1016/j.onehlt.2020.100131
resource representing a document's title	Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19
has PubMed Central identifier	PMC7128742
has PubMed identifier	32292817
schema:publication	One Health
resource representing a document's body	covid:630cf094987dd0a567cd7d4373e10928245f5dd6#body_text
is schema:about of	named entity 'mechanisms' named entity 'Our' named entity 'PATIENTS' named entity 'HYDROXYCHLOROQUINE' named entity 'WORLDWIDE' named entity 'DRAW' named entity 'TESTED' named entity 'RISK' named entity 'POST' named entity 'HOME' named entity 'HIGH' named entity 'ATTENTION' named entity 'MEDICAL' covid:arg/630cf094987dd0a567cd7d4373e10928245f5dd6 named entity 'APPEAR' named entity 'MEANING' named entity 'BENEFIT' named entity 'PUBLIC HEALTH' named entity 'ANTIVIRAL' named entity 'POTENTIAL' named entity 'EVALUATION' named entity 'ONE HEALTH' named entity 'REVIEWED' named entity 'OUR' named entity 'EFFECT' named entity 'EXPOSURE' named entity 'EFFICACY' named entity 'POSITIVE' named entity 'PEOPLE' named entity 'INCLUDING' named entity 'SCIENTISTS' named entity 'THRESHOLDS' named entity 'QUALITY' named entity 'EXPOSED' named entity 'CONSIDERATION' named entity 'CONTACT WITH' named entity 'RATIO' named entity 'TAKING' named entity 'BENEFICIAL EFFECT' named entity 'DOCTORS' named entity 'HAVE' named entity 'COALITION' named entity 'NEED FOR' named entity 'DRUG' named entity 'MECHANISMS' named entity 'WANT TO' named entity 'PROTOCOLS' named entity 'CAREGIVERS' named entity 'efficacy' named entity 'protocols' named entity 'contact' named entity 'scientists' named entity 'hydroxychloroquine' named entity 'hydroxychloroquine' named entity 'HCQ' named entity 'anosmia' named entity 'Chloroquine' named entity 'cribriform plate' named entity 'clinical trials' named entity 'lungs' named entity 'Zika' named entity 'immunomodulatory' named entity 'HCQ' named entity 'Herpes simplex virus type 1' named entity 'hyposmia' named entity 'cytotoxic' named entity 'hydroxychloroquine' named entity 'hydroxychloroquine' named entity 'Chloroquine' named entity 'HCQ' named entity 'cytotoxic' named entity 'HCQ'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software